Bavarian Nordic A/S (OMX: BAVA) upgraded its full-year 2026 financial guidance on August 21, citing continued strength in its Public Preparedness business. The Copenhagen-based vaccine company now expects total revenue of approximately DKK 5,700 million, hitting the upper end of its previous range.

The upgrade reflects a significant shift in revenue composition, with Public Preparedness contributing the bulk of the growth. The company expects DKK 2,500 million from this segment, up from a previous range of DKK 2,300–2,500 million. This contrasts with Travel Health revenue, which remains steady at DKK 3,000 million, and other revenue sources at DKK 200 million.

Revenue Drivers and Contract Backlog

The higher Public Preparedness outlook is underpinned by additional contract awards. Bavarian Nordic has secured approximately DKK 2,300 million in revenue for delivery in 2026. Furthermore, the company has locked in approximately DKK 800 million for deliveries in 2027, providing visibility into near-term future earnings.

Conversely, expectations for Vimkunya, a travel health product, were revised downward to DKK 200 million from DKK 250 million. The company attributed this reduction to lower-than-expected revenue from the US market, specifically due to the lack of publication of the ACIP recommendation in the MMWR. Despite this specific product headwind, overall Travel Health performance remained robust across the core portfolio.

Margin Expansion

Operational efficiency and a favorable revenue mix have driven an improvement in profitability metrics. The expected EBITDA margin for FY26 has been increased to approximately 30%, up from the previously guided ~28%. This expansion follows earlier upgrades from an initial guidance of 25%.

What the Numbers Show

The divergence between the Travel Health and Public Preparedness segments highlights a strategic pivot in revenue reliance. While Travel Health provides a stable base of DKK 3,000 million, the Public Preparedness segment is now projected to contribute nearly 44% of total revenue (DKK 2,500 million). The simultaneous upgrade in EBITDA margin suggests that the high-margin nature of government preparedness contracts is outweighing the dilution from lower Vimkunya sales, indicating improved operational leverage in the manufacturing and supply chain.

Guidance Progression

All other assumptions underlying the 2026 financial guidance remain unchanged as stated in the 2025 annual report.

Bavarian Nordic A/S (OMX: BAVA) announced on August 7, 2026, that the European Commission has adopted a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), approving a type II variation for its IMVANEX (MVA-BN) smallpox and mpox vaccine. The approval extends the current marketing authorization to include children aged 2 to less than 12 years, significantly broadening access to a non-replicating vaccine designed to protect vulnerable populations against mpox, smallpox, and disease caused by the vaccinia virus. This development strengthens Bavarian Nordic’s position in global public health preparedness, addressing a critical gap in pediatric protection amid recent outbreaks.

The regulatory decision relies on data from a Phase 2 clinical study (NCT06549530) co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI). The trial enrolled 227 children aged 2 to less than 12 years and 224 adults, evaluating the efficacy and safety of two standard doses of MVA-BN. Results indicated non-inferior immune responses in children compared to adults, alongside a similar safety profile. Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, emphasized that children have borne a disproportionate burden during recent mpox outbreaks, particularly in parts of Africa, highlighting the urgency of making safe vaccines available to this demographic.

Clinical Study Details

The Phase 2 study provided the foundational evidence for the expanded indication. Key parameters from the trial are summarized below:

With this approval, MVA-BN is now authorized in the European Union for use in individuals aged 2 years and older. The vaccine, marketed as IMVANEX in the EU/EEA and United Kingdom, JYNNEOS in the U.S., Switzerland, Singapore, and Mexico, and IMVAMUNE in Canada, remains the only non-replicating mpox vaccine approved across these major jurisdictions. Originally developed in collaboration with the U.S. government to ensure smallpox vaccine supply for immunocompromised individuals, MVA-BN’s expanded age range enhances its utility in general population risk mitigation.

Strategic Implications

The approval reinforces Bavarian Nordic’s role as a preferred supplier of mpox and smallpox vaccines to governments worldwide. By extending protection to younger demographics, the company addresses a key vulnerability identified in recent epidemiological trends. Chaplin noted that the collaboration with study participants, investigators, CEPI, and partners was instrumental in generating the robust data required for this regulatory milestone. The expansion supports broader public health strategies aimed at outbreak response and preparedness, particularly in regions where pediatric cases have been prominent.

What the Numbers Show

The inclusion of 227 pediatric participants in the Phase 2 trial represents a substantial dataset for this specific age cohort, providing statistical power to demonstrate non-inferiority against an adult control group of 224 individuals. The comparable safety profile observed between the two groups suggests that the non-replicating nature of MVA-BN mitigates risks often associated with traditional replicating smallpox vaccines, which are contraindicated for immunocompromised patients. This data underpins the regulatory confidence in extending the indication down to age 2, marking a pivotal shift in the vaccine’s deployment strategy for vulnerable populations.

Bavarian Nordic continues to leverage its leading portfolio of travel and epidemic preparedness vaccines to enhance global health security. The company does not undertake any obligation to publicly update forward-looking statements except as required by law, but this approval underscores its commitment to innovative vaccine solutions.